Literature DB >> 19660722

Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation.

Jonas A de Souza1, Rima M Saliba, Poliana Patah, Gabriela Rondon, Rachel Ribeiro, Leandro de Padua Silva, Muzaffar H Qazilbash, Chitra Hosing, Uday Popat, Yvonne Efebera, Richard E Champlin, Marcos de Lima.   

Abstract

Nonrelapse mortality (NRM) after reduced-intensity allogeneic transplants is likely to be influenced by abnormalities in renal function. We studied 141 patients diagnosed with acute myelogenous leukemia (AML) (n = 131) or high-risk myelodysplastic syndrome (MDS) (n = 10) who underwent allogeneic transplantation with fludarabine (Flu)/melphalan (Mel)-based regimens and hypothesized that moderate to mild renal function impairment increases NRM in this setting. Flu dose consisted of 25-30 mg/m(2) for 4 days and Mel dose was 100-180 mg/m(2). Donors were HLA-compatible siblings (n = 69) and matched unrelated donors (n = 72). Disease status at transplantation was complete remission (n = 56, 40%) or active disease (n = 85, 60%). The influence of the estimated glomerular filtration rate (GFR) measured before transplantation on outcomes was analyzed. GFR was estimated by both the Cockcroft-Gault (CG) and the modified diet in renal disease (MDRD) equations, using the creatinine value obtained prior to starting chemotherapy. Evaluated outcomes were overall survival (OS), NRM, and treatment-related mortality (TRM) at day 100 and 1-year posttransplantation. Median age was 55 years (range: 21-74 years); 59% of the patients were male. Estimated GFR by CG was > or =90 for 45 (32%), 60-89 for 78 (55%), and <60 for 18 (13%) patients. When estimated by MDRD, GFR was > or =90 for 65 (46%), 60-89 from 66 (47%), and <60 for 10 (7%) patients. The majority of patients by both estimations had a GFR between 60 and 89 (n = 78 by CG and n = 66 by MDRD) with no difference in the evaluated outcomes between this group and the subgroup of patients with a GFR <60 (P > .05). There were no differences in OS and NRM at day 100 and 1-year posttransplantation in the 3 groups by any GFR estimation method. In conclusion, a mild to moderate decrease in GFR was not associated with an increase in NRM.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19660722     DOI: 10.1016/j.bbmt.2009.05.006

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  4 in total

1.  Mild renal dysfunction defined by creatinine clearance rate has limited impact on clinical outcomes after allogeneic hematopoietic stem cell transplantation.

Authors:  Shuntaro Ikegawa; Ken-Ichi Matsuoka; Tomoko Inomata; Naoto Ikeda; Hiroyuki Sugiura; Taiga Kuroi; Takeru Asano; Shohei Yoshida; Hisakazu Nishimori; Nobuharu Fujii; Eisei Kondo; Yoshinobu Maeda; Mitsune Tanimoto
Journal:  Int J Hematol       Date:  2018-01-04       Impact factor: 2.490

Review 2.  Acute Kidney Injury and CKD Associated with Hematopoietic Stem Cell Transplantation.

Authors:  Amanda DeMauro Renaghan; Edgar A Jaimes; Jolanta Malyszko; Mark A Perazella; Ben Sprangers; Mitchell Howard Rosner
Journal:  Clin J Am Soc Nephrol       Date:  2019-12-13       Impact factor: 8.237

3.  Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation.

Authors:  Nosha Farhadfar; Ajoy Dias; Tao Wang; Caitrin Fretham; Saurabh Chhabra; Hemant S Murthy; Larisa Broglie; Anita D'Souza; Shahinaz M Gadalla; Robert Peter Gale; Shahrukh Hashmi; A Samer Al-Homsi; Gerhard C Hildebrandt; Peiman Hematti; David Rizzieri; Lynette Chee; Hillard M Lazarus; Christopher Bredeson; Edgar A Jaimes; Amer Beitinjaneh; Asad Bashey; Tim Prestidge; Maxwell M Krem; David I Marks; Stefanie Benoit; Jean A Yared; Taiga Nishihori; Richard F Olsson; Cesar O Freytes; Edward Stadtmauer; Bipin N Savani; Mohamed L Sorror; Siddhartha Ganguly; John R Wingard; Marcelo Pasquini
Journal:  Transplant Cell Ther       Date:  2021-02-26

4.  Renal Function and All-Cause Mortality Risk Among Cancer Patients.

Authors:  Yan Yang; Hui-Yan Li; Qian Zhou; Zhen-Wei Peng; Xin An; Wei Li; Li-Ping Xiong; Xue-Qing Yu; Wen-Qi Jiang; Hai-Ping Mao
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.